BIOCOG
Biomarker Development for Postoperative Cognitive Impairment in the Elderly
| Coordinatore | CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 7˙743˙063 € |
| EC contributo | 5˙982˙400 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2013-INNOVATION-1 |
| Funding Scheme | CP-FP |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-02-01 - 2019-01-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | coordinator | 1˙276˙800.00 |
| 2 |
MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT
Organization address
address: ROBERT ROSSLE STRASSE 10 contact info |
DE (BERLIN) | participant | 988˙400.00 |
| 3 |
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Organization address
address: HEIDELBERGLAAN 100 contact info |
NL (UTRECHT) | participant | 886˙600.00 |
| 4 |
PHARMAIMAGE BIOMAKER SOLUTIONS GmbH
Organization address
address: MILANSTRASSE 3 contact info |
DE (RATINGEN) | participant | 830˙800.00 |
| 5 |
ATLAS BIOLABS GMBH
Organization address
address: KERPENER STRASSE 61-69 contact info |
DE (KOLN) | participant | 625˙500.00 |
| 6 |
UNIVERSITE DU LUXEMBOURG
Organization address
address: AVENUE DE LA FAIENCERIE 162 A contact info |
LU (LUXEMBOURG-VILLE) | participant | 390˙300.00 |
| 7 |
IMMUNDIAGNOSTIK AG
Organization address
address: STUBENWALD ALLEE 8 A contact info |
DE (BENSHEIM) | participant | 300˙000.00 |
| 8 |
CONSIGLIO NAZIONALE DELLE RICERCHE
Organization address
address: Piazzale Aldo Moro 7 contact info |
IT (ROMA) | participant | 264˙000.00 |
| 9 |
ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE SRLU
Organization address
address: VIA FIORENTINA 151 contact info |
IT (SIENA) | participant | 150˙000.00 |
| 10 |
Cambridge University Hospitals NHS Foundation Trust
Organization address
address: Hills Rd contact info |
UK (Cambridge) | participant | 150˙000.00 |
| 11 |
PHYSIKALISCH-TECHNISCHE BUNDESANSTALT
Organization address
address: Bundesallee 100 contact info |
DE (BRAUNSCHWEIG) | participant | 70˙000.00 |
| 12 |
CELLOGIC GMBH
Organization address
address: C/O CONGRESSA - ENGELDAMM 62 contact info |
DE (BERLIN) | participant | 50˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Postoperative delirium (POD) is characterized by the progressive deterioration of sensory/cognitive function after surgery with incidences of up to 30-80%. It is frequently followed by postoperative cognitive dysfunction (POCD) which tends to persist over time. In elderly patients, POCD resembles chronic dementia and appears to accelerate the cognitive decline in Alzheimer dementia. POD is strongly associated with subsequent dementia after 3.2 and 5.0 years of follow-up: odds ratio = 12.52 [95% CI, 1.86-84.21] corrected for baseline dementia, severity of illness, age. In an aging society like the EU, the socioeconomic implications of POD/POCD are therefore profound. At present no treatment exists and there are no established molecular or imaging biomarkers that allow risk and clinical outcome prediction. We will establish valid biomarkers panels for risk and clinical outcome prediction of POD/POCD in N=1200 surgical patients according to the regulatory requirements of the European Medicines Agency. Thus, a valuable database will be created not yet existing worldwide. Neuroimaging investigations, which directly provide information on brain structure/function, will include structural magnetic resonance imaging (MRI), diffusion tensor imaging (DTI), arterial spin labelling (ASL), functional magnetic resonance imaging with simultaneous electrophysiology (fMRI/EEG) and glutamate MR-spectroscopy (MRS). These investigations will be complemented by genetic/gene expression analyses (sequencing of cholinergic candidate genes/corresponding transcripts) and analyses of plasma and cerebrospinal fluid markers (inflammatory/metabolic). Supported by bioinformatics approaches, integration of neuroimaging data with knowledge from molecular biomarkers (multivariate expert system) is expected to allow patient stratification. This will greatly support decision-making before surgical intervention (balancing benefits and risks) as well as the development of novel therapies in POD/POCD.'